Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was EGP 456.23 million compared to EGP 392 million a year ago. Net income was EGP 57.01 million compared to EGP 66.51 million a year ago.

Basic earnings per share from continuing operations was EGP 0.0382 compared to EGP 0.0452 a year ago. Diluted earnings per share from continuing operations was EGP 0.0382 compared to EGP 0.045 a year ago.